Scott A. Gangloff
CIK 1663253 · Chief Technology Officer · last filed 2025-12-09
Scott A. Gangloff is a Chief Technology Officer who has filed 8 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for AKRO, was dated Dec 9, 2025. Across all open-market trades the lifetime net is −$186.6K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
8
-$186.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) Delisted | Chief Technology Officer | 0 | $54.65 | $0 | -$46.5K | 6 | 2025-12-09 |
| Outlook Therapeutics, Inc. (ONSIZ) Delisted | SVP, Development & Mfrg | 118,573 | — | — | -$140.1K | 2 | 2016-12-22 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −26,351 | $0 | EDGAR |
| 2025-08-19 | Akero Therapeutics, Inc. (AKRO) Delisted | Exer (M) | +2,600 | $51.0K | EDGAR |
| 2025-07-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +299 | $7.1K | EDGAR |
| 2025-06-20 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −848 | -$46.5K | EDGAR |
| 2024-12-18 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +24,300 | $0 | EDGAR |
| 2024-05-01 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-22 | Outlook Therapeutics, Inc. (ONSIZ) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2016-11-14 | Outlook Therapeutics, Inc. (ONSIZ) Delisted | Mixed | −37,369 | -$140.1K | EDGAR |